I don't think it is necessarily anything that negative. It is normal for there to be delays during the IND process due to the FDA requiring more information and/or needing certain issues to be addressed. My point is that looking at the recent PR as a positive event is sort of ridiculous. As you said on BMSN's board, it is more of a neutral one. Anyone who has taken the time to review the IND process knows that the IND number is issued following official receipt by the FDA. Meaning, it should have presented to us around the time they claimed to have filed the IND application on February 5th. Yet, they announce it almost a month and a half later. People argue that it shows backbone by the company (which I agree with) but all things considered it is no different than their announcement on February 5th. What happened between February 5th and March 18th? if the IND application was placed on hold, this information should have been given to us within 30 calender days. If we were given the green light to begin clinical trials, this information should have been presented within 34 days (30 calender days for review and 4 business days to disclose a material event.) If people look at other examples, this has always been the case unless there was an announced reason for delay. I look at the PR as fluff to hold people over, because announcing they received an IND # is really no different than square one on February 5th. There is clearly information being withheld, and David Koos is choosing to only announce news that can be seen in a positive light. Why can't he disclose to exact date the FDA received the IND application instead of being vague about it? I still believe in BMSN, but I will remain realistic in doing so.
AI
